Transcutaneous immunization of Streptococcus suis bacterin using dissolving microneedles. (February 2017)

• Record Type: Journal Article
• Authors: Hsueh, Kai-Jen; Chen, Mei-Chin; Cheng, Li-Ting; Lee, Jai-Wei; Chung, Wen-Bin; Chu, Chun-Yen
• Is Part Of: Comparative immunology, microbiology and infectious diseases. Volume 50(2017)
• Page Start: 78
• Page End: 87
• Publication Date: 2017-02
• Subjects: Microneedles (MNs) -- Streptococcus suis -- Transcutaneous immunization; Communicable diseases in animals -- Periodicals; Veterinary immunology -- Periodicals; Veterinary microbiology -- Periodicals; Immunology -- Periodicals; Microbiology -- Periodicals; Communicable diseases -- Periodicals; Communicable Diseases -- immunology -- Periodicals; Communicable Diseases -- veterinary -- Periodicals; Allergy and Immunology -- Periodicals; Microbiology -- Periodicals; Veterinary Medicine -- Periodicals; Immunologie -- Périodiques; Microbiologie -- Périodiques; Maladies infectieuses -- Périodiques; Communicable diseases; Immunology; Microbiology; Electronic journals; Periodicals; 636.08969
• DOI: 10.1016/j.cimid.2016.12.001
• Languages: English
• ISSNs: 0147-9571

Abstract

Highlights: Dissolving microneedle vaccine containing S. suis 2 bacterin was evaluated in mice. Microneedles induce TH 1-type cytokine production, antibody response, and strong T cell proliferation. Single-dose microneedle vaccination provides higher protection rate in challenge test than intramuscular vaccination. Single-dose microneedle vaccination maintains TH1-type antibody levels for up to 7 months. Abstract: Vaccine delivery using microneedle (MN) patches is an easy, safe and painless alternative to traditional needle injections. In this study, we examined whether MN patches can enhance the efficacy of a Streptococcus suis serotype 2 ( S. suis 2) vaccine in a mouse model. Results showed that MNs can reach 200–250 μm into the skin, a depth beneficial for targeted delivery of antigens to antigen-presenting cells in the epidermis and dermis. Vaccination with prime-boost of MN induced higher levels of IgG2a antibody titer, T cell proliferation, and TH 1 cytokines (IFN-γ and IL-12) as compared to intramuscular (IM) injection. In addition, single dose MN vaccination better protected mice against lethal challenge than IM vaccination. MN vaccination also conferred long-term IgG2a antibody against S. suis 2 bacteria presence for up to 7 months. Taken together, these data showed that vaccine delivery by MNs results in superior immune response and protection rate when compared to IM injections.